2020
Genetic characterization of an aggressive optic nerve pilocytic glioma
Hong CS, Fliney G, Fisayo A, An Y, Gopal PP, Omuro A, Pointdujour-Lim R, Erson-Omay EZ, Omay SB. Genetic characterization of an aggressive optic nerve pilocytic glioma. Brain Tumor Pathology 2020, 38: 59-63. PMID: 33098465, PMCID: PMC7585354, DOI: 10.1007/s10014-020-00383-x.Peer-Reviewed Original ResearchConceptsOptic nerve gliomaLeft optic nerve sheathLeft-sided visual lossSporadic adult casesOptic nerve sheathNeurofibromatosis type 1 syndromeType 1 syndromeWhole-exome sequencingEmpiric managementVisual lossFocal radiotherapyOptic nervePediatric populationNerve sheathOpen biopsyAdult casesBiopsy specimenBenign histopathologyClinical prognosticationPilocytic astrocytomaComplex tumorsActionable targetsVisual pathwayAdult populationTumor progression
2019
Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging
Thulborn KR, Lu A, Atkinson IC, Pauliah M, Beal K, Chan TA, Omuro A, Yamada J, Bradbury MS. Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging. Clinical Cancer Research 2019, 25: 1226-1232. PMID: 30487127, PMCID: PMC7462306, DOI: 10.1158/1078-0432.ccr-18-2079.Peer-Reviewed Original ResearchConceptsResidual tumor volumeTumor cell killTissue sodium concentrationChemoradiation therapyOverall survivalHuman glioblastomaTumor volumeQuantitative sodium MR imagingCell killQuantitative sodium MRITumor cellsVariable tumor responseSodium MRITwo-compartment modelTumor resectionTumor responseDisease progressionSodium MR imagingTumor marginsMR imagingTherapyGlioblastomaTreatment volumeCancer cellsSodium concentrationBuparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial
Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, S. A, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. Journal Of Clinical Oncology 2019, 37: jco.18.01207. PMID: 30715997, PMCID: PMC6553812, DOI: 10.1200/jco.18.01207.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAminopyridinesAntineoplastic AgentsBrain NeoplasmsChemotherapy, AdjuvantDisease ProgressionEnzyme ActivationFemaleGlioblastomaHumansMaleMiddle AgedMorpholinesNeoadjuvant TherapyNeoplasm Recurrence, LocalPhosphatidylinositol 3-KinasePhosphoinositide-3 Kinase InhibitorsProgression-Free SurvivalTime FactorsConceptsPhase II trialCohort 2Cohort 1PI3K pathwayTumor tissueII trialRecurrent glioblastomaBrain penetrationPan-PI3K inhibitor buparlisibPathway inhibitionPathway activationCommon grade 3K pathwayPrimary end pointGreater adverse eventsProgression-free survivalPI3K pathway inhibitionPI3K pathway activationPlasma drug levelsSingle-agent efficacySignificant brain penetrationPI3K inhibitorsMedian PFSOpen labelAdverse events
2015
Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non–small cell lung cancer
Nayak L, DeAngelis LM, Robins HI, Govindan R, Gadgeel S, Kelly K, Rigas JR, Peereboom DM, Rosenfeld SS, Muzikansky A, Zheng M, Urban P, Abrey LE, Omuro A, Wen PY. Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non–small cell lung cancer. Cancer 2015, 121: 4165-4172. PMID: 26308485, PMCID: PMC5941922, DOI: 10.1002/cncr.29636.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerProgressive brain metastasesBrain metastasesCell lung cancerAdverse eventsStudy drugLung cancerGrade 3/4 adverse eventsMulticenter phase 2 studyNSCLC brain metastasesSteady-state distribution volumePhase 1/2 studyRecurrent brain metastasesPhase 2 studyProgression-free survivalFirst prospective studyConcentration-time curvePrimary endpointAdult patientsOverall survivalPulmonary embolismMedian agePeripheral neuropathyMedian timeProspective studyGlutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo
Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, Campos C, Carlin SD, La Rocca G, Lyashchenko S, Ploessl K, Rohle D, Omuro AM, Cross JR, Brennan CW, Weber WA, Holland EC, Mellinghoff IK, Kung HF, Lewis JS, Thompson CB. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Science Translational Medicine 2015, 7: 274ra17. PMID: 25673762, PMCID: PMC4431550, DOI: 10.1126/scitranslmed.aaa1009.Peer-Reviewed Original ResearchMeSH KeywordsBlood-Brain BarrierBrain NeoplasmsDisease ProgressionFluorine RadioisotopesGliomaGlutamineHumansPositron-Emission TomographyConceptsPositron emission tomographyPermeable blood-brain barrierChemo/radiation therapyHigh tumor/background ratiosClear tumor delineationDecreased tumor burdenHigh background uptakeTumor/background ratiosBlood-brain barrierAltered glucose metabolismHuman glioma patientsVivo positron emission tomographyProgressive diseaseTumor burdenMetabolic evaluationBrain uptakeClinical managementTumor avidityGlioma patientsRadiation therapyGlucose metabolismBackground uptakeEmission tomographyGliomasCancer cellsDiffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence
Prager A, Martinez N, Beal K, Omuro A, Zhang Z, Young R. Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence. American Journal Of Neuroradiology 2015, 36: 877-885. PMID: 25593202, PMCID: PMC4731220, DOI: 10.3174/ajnr.a4218.Peer-Reviewed Original ResearchConceptsTreatment-related changesRecurrent tumorsHigh-grade gliomasSurgical resectionRecurrent high-grade gliomaLow relative cerebral blood volumeSubanalysis of patientsUtility of DWIRelative cerebral blood volumeTreatment-related effectsCerebral blood volumeWilcoxon rank sum testConventional MR imagingRank sum testConsecutive patientsHistopathologic evidenceMass lesionDSC perfusionRadiation therapyBlood volumeGrade gliomasPatientsLow perfusionTumorsDSC maps
2014
Methotrexate re-challenge for recurrent primary central nervous system lymphoma
Pentsova E, DeAngelis LM, Omuro A. Methotrexate re-challenge for recurrent primary central nervous system lymphoma. Journal Of Neuro-Oncology 2014, 117: 161-165. PMID: 24481997, PMCID: PMC5256683, DOI: 10.1007/s11060-014-1370-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntimetabolites, AntineoplasticCentral Nervous System NeoplasmsDisease ProgressionDisease-Free SurvivalFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMethotrexateMiddle AgedNeoplasm Recurrence, LocalPrognosisRetreatmentRetrospective StudiesSalvage TherapyTreatment OutcomeConceptsPrimary CNS lymphomaKarnofsky performance scoreProgression-free survivalInitial diagnosisRecurrent primary central nervous system lymphomaPrimary central nervous system lymphomaMedian Karnofsky performance scoreMedian progression-free survivalCentral nervous system lymphomaObjective response rateNervous system lymphomaMedian OSCNS lymphomaFree survivalRecurrent diseaseSalvage treatmentFirst relapsePartial responsePCNSL patientsPrognostic factorsComplete responseMedian ageSystem lymphomaDisease relapseMedian time
2012
MRI perfusion in determining pseudoprogression in patients with glioblastoma
Young RJ, Gupta A, Shah AD, Graber JJ, Chan TA, Zhang Z, Shi W, Beal K, Omuro AM. MRI perfusion in determining pseudoprogression in patients with glioblastoma. Clinical Imaging 2012, 37: 41-49. PMID: 23151413, PMCID: PMC4755513, DOI: 10.1016/j.clinimag.2012.02.016.Peer-Reviewed Original ResearchChemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis
Pentsova E, Rosenblum M, Holodny A, Palomba ML, Omuro A. Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis. Leukemia & Lymphoma 2012, 53: 1620-1622. PMID: 22242822, DOI: 10.3109/10428194.2012.656632.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic AgentsAutopsyBrainBrain InjuriesChlorambucilCytarabineDisease ProgressionFatal OutcomeHumansInjections, SpinalLeukemia, Lymphocytic, Chronic, B-CellMagnetic Resonance ImagingMaleMethotrexateNervous System DiseasesPositron-Emission TomographyRecurrenceWaldenstrom Macroglobulinemia
2011
Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma
Young R, Gupta A, Shah A, Graber J, Zhang Z, Shi W, Holodny A, Omuro A. Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology 2011, 76: 1918-1924. PMID: 21624991, PMCID: PMC3115805, DOI: 10.1212/wnl.0b013e31821d74e7.Peer-Reviewed Original ResearchConceptsEarly progressionMRI signsNegative predictive valuePredictive valueFinal diagnosisHigh negative predictive valueUseful MRI markerFisher's exact testSubependymal spreadSecond resectionRetrospective studyMass lesionSurgical specimensMRI markersPotential utilityClinical physiciansExact testMRI scansPatientsSubependymal enhancementLesionsGlioblastomaPseudoprogressionSignsDiagnosis